Group 1 - The core revenue growth is driven by the medical aesthetics business, which generated approximately RMB 1.485 billion in revenue, a year-on-year increase of about 99.6% [1] - The core product, Letibao, expanded its coverage to over 8,000 medical beauty institutions and 1,500 key institutions, contributing to steady revenue growth [1] - The innovative drugs and other pharmaceuticals generated approximately RMB 176 million, a year-on-year increase of about 206.3%, primarily due to increased sales of diabetes medications [1] Group 2 - The year 2026 is critical for the company’s strategic transformation and high-quality development, marking the beginning of its three-year strategic plan [2] - The company aims to become a benchmark enterprise in the Chinese medical aesthetics industry by focusing on compliance, growth in regenerative materials and collagen protein, and personalized anti-aging solutions [2] - The core strategy includes deepening dual-driven growth, releasing synergistic value, accelerating global layout, and enhancing capital efficiency [2] Group 3 - The total revenue for the year ending December 31, 2025, was approximately RMB 2.618 billion, a year-on-year increase of about 37.7% [3] - Gross profit was approximately RMB 1.802 billion, a year-on-year increase of about 45.1%, while overall research and development expenses were approximately RMB 291 million, a decrease of 38.5% [3] - The company reported a profit attributable to shareholders of approximately RMB 180 million, turning a profit compared to the previous year, with basic earnings per share of 1.97 cents [3]